SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy

Must have received: radical prostatectomy

after RP

Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy

Prior-therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)

Cannot have received: systemic anti-cancer therapy (neo-adjuvant androgen deprivation therapy (ADT), secondary hormone ablation, taxan-based chemotherapy)

Prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to registration (like neo-adjuvant androgen deprivation therapy (ADT), secondary hormone ablation or taxan-based chemotherapy)

Cannot have received: radiation therapy

Prior radiotherapy within 4 weeks before start of study medication